Antiphospholipid antibodies and HLA associations in primary Sjogren's syndrome.

Ra, Asherson; Fei, Hongming; Staub, Henrique Luiz; Khamashta, M. A.; Hughes, G. R. V.; Fox, Robert I.

doi:10.1136/ard.51.4.495

Cited by 40 publications

(16 citation statements)

References 29 publications

(8 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In other studies the occurrence of anticardiolipin antibodies in patients with primary Sjogren's syndrome varied from 5 to 52%.9 10 12 23 They were identified in 7 to 13% of patients with rheumatoid arthritis8 " 1 24 and in 82% ofpatients with Sjogren's syndrome secondary to rheumatoid arthritis. 23 The isotypes of anticardiolipin antibodies in patients with primary Sjogren's syndrome have been previously studied by some workers9 10 12 In our patients there was no correlation between anticardiolipin antibodies and any extraglandular manifestations of the disease.…”

Section: Discussionmentioning

confidence: 91%

Isotype profile and clinical relevance of anticardiolipin antibodies in Sjogren's syndrome.

Jędryka-Góral

Jagiello

D’Cruz

et al. 1992

Annals of the Rheumatic Diseases

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 91%

Isotype profile and clinical relevance of anticardiolipin antibodies in Sjogren's syndrome.

Jędryka-Góral

Jagiello

D’Cruz

et al. 1992

Annals of the Rheumatic Diseases

Self Cite

View full text Add to dashboard Cite

show abstract

“…[14][15][16][17][18] In our study, antiphospholipid antibodies were not systematically tested in the patients although at least three pSS patients were positive for antiphospholipid antibodies. Future studies investigating whether the presence of antiphospholipid antibodies affect TEG/MEA parameters is worthwhile.…”

Section: Discussionmentioning

confidence: 99%

“…First, pSS patients may have abnormal lipid profiles, 11 accelerated atherosclerosis 12 and increased prevalence of diabetes 13 and hypertension (unpublished observations), all of which are risk factors for thromboembolic diseases. In addition, it has been reported that the prevalence of antiphospholipid antibodies is increased among pSS patients, [14][15][16][17][18] which in turn may increase the thromboembolic risk. Second, there is an increase in microparticles, small membrane-bound vesicles secreted from activated/apoptotic cells, in pSS patients compared with controls and SLE patients.…”

Section: Strengths and Limitations Of This Studymentioning

confidence: 99%

Assessment of blood clot formation and platelet receptor function ex vivo in patients with primary Sjögren's syndrome

et al. 2013

View full text Add to dashboard Cite

ObjectivesPrimary Sjögren's syndrome (pSS) shares clinical features and pathogenetic mechanisms with systemic lupus erythematosus (SLE). SLE is associated with an increased thromboembolic risk; however, it is unclear whether pSS patients are susceptible to thromboembolic diseases. In this study, we examined ex vivo blood clot formation (clot strength, rates of clot formation and lysis) in pSS using thromboelastography (TEG) and platelet aggregation to common agonists using multiple electrode aggregometry (MEA). We also investigated the relationship between TEG/MEA parameters and clinical/laboratory features of pSS.DesignCase control.SettingSecondary care, single centre.Participants34 pSS patients, 11 SLE patients and 13 healthy volunteers (all women) entered and completed the study.Primary and secondary outcome measuresPrimary outcomes: TEG and MEA parameters between three subject groups. Secondary outcomes: The relationships between TEG/MEA and clinical/laboratory parameters analysed using bivariate correlation analysis with corrections for multiple testing.ResultsAll TEG and MEA parameters were similar for the three subject groups. After corrections for multiple testing, interleukin (IL)-1α and Macrophage inflammatory proteins (MIP)-1α remain correlated inversely with clot strength (r=−0.686, p=0.024 and r=−0.730, p=0.012, respectively) and overall coagulability (r=−0.640, p=0.048 and r=−0.648, p=0.048). Stepwise regression analysis revealed that several cytokines such as MIP-1α, IL-17a, IL-1α and Interferon (IFN)-γ may be key predictors of clot strength and overall coagulability in pSS.ConclusionsClot kinetics and platelet receptor function are normal in pSS. Several cytokines correlate with clot strength and overall coagulability in pSS.

show abstract

“…Genetic risk factors such as STAT-4 , IL-T6 , haplotype HLA DRw52-DR2-DR3-B8 , the heterozygosity of the HLA-DQ genetic locus [12] and, more recently, IRF5 , have been identified [13]. The association between HLA and SS is restricted to patients with anti-Ro/or anti-La antibodies [14,15].…”

Section: Etiopathogenesismentioning

confidence: 99%

Serologic features of primary Sjögren’s syndrome: clinical and prognostic correlation

Garcı́a-Carrasco¹,

Mendoza‐Pinto²,

Jiménez-Hernández³

et al. 2012

International Journal of Clinical Rheumatology

View full text Add to dashboard Cite

Sjögren’s syndrome (SS) is a chronic inflammatory systemic autoimmune disease. The disease spectrum extends from sicca syndrome to systemic involvement and extraglandular manifestations, and SS may be associated with malignancies, especially non-Hodgkin’s lymphoma. Patients with SS present a broad spectrum of serologic features. Certain serological findings are highly correlated with specific clinical features, and can be used as prognostic markers.

show abstract

Antiphospholipid antibodies and HLA associations in primary Sjogren's syndrome.

Cited by 40 publications

References 29 publications

Isotype profile and clinical relevance of anticardiolipin antibodies in Sjogren's syndrome.

Isotype profile and clinical relevance of anticardiolipin antibodies in Sjogren's syndrome.

Assessment of blood clot formation and platelet receptor function ex vivo in patients with primary Sjögren's syndrome

Serologic features of primary Sjögren’s syndrome: clinical and prognostic correlation

Contact Info

Product

Resources

About